Celebrating Leica Biosystems - a leader in automatic staining, bright field, and fluorescence imaging technology, and recently acquiring Cell IDx, a leader in tissue multiple staining and analysis. CellIDx was founded in 2012 and is headquartered in San Diego. It provides multiple staining schemes, tissue staining, imaging, and analysis services,

Cell lDx's UltraPlex technology can detect multiple biomarkers simultaneously using fluorescence and bright field multiple immunohistochemistry (IHC) staining reagents on Leica Biosystems' BOND RX fully automated scientific staining machine. The combination of UltraPlex, BOND RX, and high-throughput imaging instruments enables researchers to detect three or more biomarkers on a single slice in a single pathological workflow.

2021
Leica Biosystems and Cell IDx have announced a partnership to integrate the product advantages of UltraPlex and BOND RX.

2022
Leica Biosystems has acquired Cell lDx to further strengthen its partnership, enhance its scale advantage, and provide medical and scientific affairs support to CelllDx clients.

Gustavo Perez Fernandez, President of Leica Biosystems, said:
We sincerely welcome Cell lDx to join the Leica Biosystems team. This acquisition will expand our potential in the field of translational research, helping researchers accelerate scientific exploration and achieve translational results.

David Schwartz, co-founder and former CEO of Cel IDx, stated
The ability to distinguish multiple target molecules in the bright field has always been an unmet requirement in clinical pathology. For example, bright field multiple IHC enables pathologists to detect target molecules inside and outside tumors. These data on a single tissue slice may provide information for real-time treatment decisions and generate a more targeted patient-centered treatment approach. Bringing this technology to researchers will drive tumor diagnosis and improve quality of life. We are pleased to contribute to this mission.

Robert Monroe, Chief Medical Officer of Leica Biosystems, agrees with Schwartz's view on the value of UltraPlex and states that Cell lDx technology promotes the transformation of complex multiple IHC staining into manageable triple and quadruple biomarker detection schemes, which can automatically perform high-quality, repeatable staining on Leica Biosystems' BOND RX platform. We believe that the integration of UltraPlex and BOND automation can serve as an emerging next-generation tissue diagnostic platform to better predict treatment response and tumor behavior.